Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

Reported by Yahoo Finance · Published 11 Sep 2026, 2:20 AM MYT (1 d ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

Robinhood CEO says companies shouldn't get veto over stock tokens in AMC feud 2 hr ago AI startup Discovery Loop seeks around $50 billion valuation, Business Insider reports 2 hr ago Exclusive-Nvidia in talks to invest in Anthropic’s mega IPO, sources say 2 hr ago OpenAI agents attacked software service RubyGems before Hugging Face incident, WSJ reports 3 hr ago OpenAI agents attacked RubyGems before Hugging Face incident, researchers say 3 hr ago S&P 500 ends higher as strong inflation data cements rate-hike bets 4 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

Summary

More in Markets

Marvell is sitting on an incredibly ‘sticky’ business that could help it unlock a $30 billion opportunity

‘I’m the executor’: My two siblings and I inherited an IRA. Can we just cash it out?

Why Dell and HPE were the S&P 500’s top-performing stocks today

I’m a single 58-year-old veteran in California with $1.5 million and a VA pension. Can I retire?

The Houthis have opened a new front in the Middle East oil war that’s pushing up prices

Salesforce’s stock has been riding a wave of AI optimism. Here’s what Wall Street wants to see next.